Cancer is Vietnam's second leading cause of death. According to the Vietnam National Cancer Institute, approximately 182,000 new cancer cases are diagnosed annually, with over 120,000 deaths. The majority of these deaths are preventable — not through a cure, but through early detection and risk-stratified prevention guided by genetic insight.
The Genetic Architecture of Cancer Risk
Not all cancer risk is genetic. Environmental exposures — tobacco, Helicobacter pylori infection, hepatitis B virus — account for a substantial proportion of Vietnam's cancer burden. But for a significant subset of cancer cases, particularly early-onset cancers and those clustering in families, inherited genetic variants play a decisive role.
These hereditary risk variants — often called germline mutations — are present in every cell of the body and can be detected through a simple DNA test. They don't guarantee cancer will develop; they indicate substantially elevated probability that, when known, enables proactive intervention.
BRCA1 and BRCA2: Beyond Western Breast Cancer Statistics
BRCA1 and BRCA2 are the most well-known cancer-predisposition genes. Pathogenic variants in BRCA1 confer lifetime breast cancer risk of up to 72%, and BRCA2 variants increase ovarian cancer risk to approximately 44%. These numbers, derived primarily from studies in women of Ashkenazi Jewish and European descent, are frequently cited in Vietnamese clinical settings — yet they may not accurately reflect risk in Vietnamese BRCA variant carriers.
GeneStory's research, using our cohort of 10,000+ Vietnamese individuals, has identified important distinctions: the specific BRCA1/2 variants most prevalent in Vietnam differ from those common in European populations. This matters clinically because variant pathogenicity can be population-specific — a variant classified as benign based on European frequency data may behave differently in Vietnamese genetic background. Our database allows clinicians to make evidence-based classifications for Vietnamese-specific BRCA variants.
Key Cancer Genes Analyzed by GeneStory
Gastric and Colorectal Cancer: A Vietnamese Priority
Vietnam has among the highest rates of gastric cancer in Southeast Asia — a legacy of widespread H. pylori infection compounded by genetic susceptibility factors. GeneStory analyzes variants in CDH1 (hereditary diffuse gastric cancer), APC (familial adenomatous polyposis), and MLH1, MSH2, MSH6, and PMS2 genes associated with Lynch syndrome — the most common hereditary colorectal cancer syndrome.
Lynch syndrome carriers face lifetime colorectal cancer risks of 52–82% and gastric cancer risks of up to 13%. For individuals identified through GeneStory's screening, the clinical response is clear: annual colonoscopy surveillance from age 25, H. pylori eradication, and gastroscopic surveillance. Early detection in Lynch syndrome carriers reduces cancer mortality by over 60%.
Liver Cancer: The ALDH2 Connection
Vietnam has one of the world's highest rates of hepatocellular carcinoma (liver cancer), driven primarily by chronic hepatitis B infection. But genetic variants also modify risk: the ALDH2*2 variant — present in approximately 30% of Vietnamese individuals — impairs acetaldehyde metabolism, dramatically increasing liver cancer risk in individuals who drink alcohol. ALDH2*2 carriers who drink even moderate amounts of alcohol experience acetaldehyde accumulation that is directly carcinogenic.
GeneStory's health report identifies ALDH2 status — providing carriers with a compelling, personalized evidence base for alcohol avoidance that goes far beyond general public health messaging.
Lung Cancer Susceptibility
While tobacco remains the dominant lung cancer risk factor, genetic variants in TERT, CHRNA5, and multiple GWAS-identified loci modify lung cancer susceptibility. In Vietnam, where smoking rates among men exceed 45%, identifying high-risk genetic profiles can guide targeted low-dose CT screening recommendations for those at greatest risk.
From Risk to Action: The Clinical Framework
Genetic risk information is only as valuable as the clinical response it enables. GeneStory's cancer prevention module doesn't just identify risk — it maps risk levels to evidence-based clinical recommendations:
- High-risk variants (BRCA1/2, Lynch syndrome, CDH1) → referral to genetic counseling, specialist surveillance programs, consideration of risk-reducing interventions
- Moderate-risk variants (ATM, CHEK2, PALB2) → enhanced screening protocols, lifestyle modification guidance, family cascade testing recommendations
- Polygenic risk scores (PRS) → population-level risk stratification for breast, colorectal, and prostate cancer, calibrated for Vietnamese allele frequencies
GeneStory works in partnership with oncology centers at Bach Mai Hospital (Hanoi) and Cho Ray Hospital (Ho Chi Minh City) to ensure that customers with significant findings receive appropriate clinical follow-up. Genetic counselors are available to discuss findings with patients and their families.
The Cascade Testing Multiplier
One of the most powerful aspects of hereditary cancer risk identification is its multiplier effect through families. When one person is identified as a BRCA1 carrier, first-degree relatives (parents, siblings, children) each have a 50% probability of carrying the same variant. A single positive test result can prompt family-wide genetic counseling and screening that identifies multiple at-risk individuals before a single cancer develops.
In Vietnamese culture, where family bonds are central and health decisions are often made collectively, this cascade testing model is particularly effective. GeneStory provides family testing packages specifically designed to support cascade testing within Vietnamese families who share a significant genetic finding.
The Future: Cancer Prevention as Public Health
Vietnam is at an inflection point. The combination of rising cancer incidence, improving genomic testing access, and a growing precision medicine infrastructure creates the conditions for a genuinely population-level shift in cancer prevention. GeneStory is working with the Ministry of Health to develop proposals for hereditary cancer risk screening programs modeled on successful frameworks in South Korea and Taiwan.
The goal is ambitious: a Vietnam where no family learns about hereditary cancer risk only after the first family member has died from it.
